Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Het 2020 GOLD Science Committee-rapport over COVID-19 en COPD
mrt 2021 | COPD, Pneumonie, Virale infecties